Nonhomologous end joining key factor XLF enhances both 5-florouracil and oxaliplatin resistance in colorectal cancer

Nonhomologous end joining key factor XLF enhances both 5-florouracil and oxaliplatin resistance in colorectal cancer

Zhuo Liu,1 Miao Yu,1 Bingyuan Fei,1 Jing Sun,2 Dongxin Wang3 1Department of Gastrointestinal Colorectal and Anal Surgery, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130021, China; 2Department of Biochemistry and Molecular Medicine, The George Washington University, W...

Full description

Bibliographic Details
Main Authors: Liu Z, Yu M, Fei B, Sun J, Wang D
Format: Article
Language:English
Published: Dove Medical Press 2019-03-01
Series:OncoTargets and Therapy
Subjects:
XLF
NHEJ
5-Fu
Oxaliplatin
chemoresistance
colorectal cancer
Online Access:https://www.dovepress.com/nonhomologous-end-joining-key-factor-xlf-enhances-both-5-florouracil-a-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/nonhomologous-end-joining-key-factor-xlf-enhances-both-5-florouracil-a-peer-reviewed-article-OTT

Similar Items